Two things worth your attention this morning, and they could not be more different.
The first is Lilly doing what Lilly does. The company agreed to acquire AtaiBeckley for up to $3.8 billion, its boldest step into psychedelic based mental health treatment and, by our count, roughly its fifteenth deal of 2026. Think about what that number means. One company has done fifteen deals in seven months, spanning obesity, oncology, cell therapy, gene editing, vaccines, pain, and now psychedelics. This is the most aggressive dealmaking machine the industry has ever seen. When Lilly pays billions for psychedelics, psychedelics stop being a curiosity and start being a market.
The second is the deadline. Today the five named companies must answer the House Select Committee on China about their trials in Xinjiang and at military hospitals. Those answers go to the committee, not to a press release, so do not expect a clean public reveal today. But the month already told the story. The political pressure did not slow the industry’s rush into Chinese science. The deals never stopped.
And in between those two stories: Merck won FDA approval for the first oral PCSK9 inhibitor, cracking open a cholesterol drug class that until now meant injections. Novo’s Wegovy pill cleared Europe. And Merck’s sac TMT hit another Phase 3, this time in endometrial cancer.
Lilly Just Made Psychedelics a Real Market
What Happened: Lilly agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion, one of the largest moves any big pharma has made into psychedelic based mental health medicines.
Why This Changes the Category
Psychedelics have spent years in a strange liminal space. The science has been building steadily—psilocybin and related compounds have shown genuine, durable effects in treatment resistant depression, a condition where existing drugs fail a large share of patients. Compass Pathways’ durable Phase 3 data last week reinforced that the effects can persist weeks or months after a single administration. But the field has been held back by three things: trial designs that are inherently difficult to blind (patients generally know if they are on a psychedelic), a regulatory path the FDA had not clearly defined, and the reputational baggage that comes with a category most people associate with counterculture rather than clinical medicine.
Lilly putting billions behind psychedelics addresses all three at once. A company with Lilly’s regulatory sophistication can design the pivotal trials and engage the FDA on the pathway. Its balance sheet can fund the development through whatever timeline the regulatory process demands. And its institutional credibility gives the category the legitimacy it lacked when it was carried by small, underfunded specialty companies that struggled to raise capital and command respect from physicians.
This is roughly Lilly’s fifteenth deal of the year. The portfolio now spans obesity (Foundayo, Zepbound, retatrutide), oncology (CrossBridge ADC, Kelonia in vivo CAR T, Orna circular RNA CAR T), gene editing (Profluent, Ascidian), vaccines (Curevo, LimmaTech, Vaccine Company), pain (4E Therapeutics MNK inhibitors), myelofibrosis (Ajax), kidney disease (Ascidian RNA exon editing), narcolepsy (Centessa), non viral gene delivery (Engage), China partnerships (Hengrui via Kailera, Haisco, Abbisko), and now psychedelic mental health (AtaiBeckley). Fifteen deals across at least ten therapeutic areas in seven months. No pharmaceutical company has ever executed this breadth at this pace.
What This Means for the Treatment Resistant Depression Market
Treatment resistant depression is one of the largest unmet needs in psychiatry. Millions of patients fail to respond adequately to first and second line antidepressants. The options after that are limited: esketamine (Spravato, from J&J), electroconvulsive therapy, or cycling through more medications with diminishing returns. The market has been desperate for something genuinely new.
Psychedelic based therapies offer a fundamentally different approach. Rather than daily medication that modulates neurotransmitter levels, the psychedelic model involves a small number of supervised administrations that appear to produce lasting changes in brain connectivity and emotional processing. If the Phase 3 data hold up across larger populations and longer follow up, this could become one of the most important new treatment modalities in psychiatry.
Lilly entering the field with $3.8 billion also changes the competitive landscape for every other company in the psychedelic space. Compass Pathways, as the leading independent psychedelic company with durable Phase 3 data, just became more valuable because Lilly’s move implies the major pharmaceutical companies will compete for these assets. Other big pharmas that dismissed psychedelics now need a position. The field just went from fringe to front page.
Our Pro brief analyzes what the deal means for Compass, the broader psychedelic category, and the treatment resistant depression market. [Details below.]
Merck Cracked the First Oral PCSK9, and That Is a Big Deal for Cholesterol Care
What Happened: The FDA approved Merck’s Lipfendra (enlicitide) as the first oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with hypercholesterolemia.
Why Format Matters as Much as Mechanism in Chronic Disease
PCSK9 inhibitors are powerful cholesterol drugs. Amgen’s Repatha and the Sanofi and Regeneron drug Praluent built the class and proved the mechanism works: potent LDL lowering that reduces cardiovascular events in patients who need more than statins alone. But both are injectables. And injection is a real barrier in a chronic, largely asymptomatic condition where patients and physicians default to the convenience of a pill.
The result: uptake of the injectable PCSK9 drugs never matched their clinical value. A needle is a hard sell for high cholesterol when oral statins are sitting right there. Patients who need more LDL lowering often settle for suboptimal statin doses or add ezetimibe rather than start an injection they will take for years.
An oral PCSK9 removes that barrier entirely. Lipfendra slots into the existing prescribing habit for cholesterol—a daily pill—while delivering the potent LDL lowering that only the PCSK9 mechanism provides. The addressable population is enormous: patients who need more than a statin but do not want to inject, statin intolerant patients who need an alternative, and patients whose LDL stays elevated despite current therapy.
This is the kind of format breakthrough that expands a market rather than just splitting it. When a powerful mechanism moves from injection to oral, the number of patients who access it typically increases substantially, because the barrier that kept patients away was not the science but the delivery. For Merck, which needs to diversify its revenue base ahead of the Keytruda patent cliff in 2028, an oral PCSK9 in one of the largest chronic disease markets in medicine is a meaningful franchise addition.
For Amgen, Sanofi, and Regeneron, the competitive dynamics shift. They built the PCSK9 class as injectables. An oral competitor from Merck changes the conversation that physicians have with patients about cholesterol treatment escalation. The injectable drugs will continue to have a role, particularly for patients who prefer less frequent dosing (monthly or biweekly injections versus daily pills). But the default for most patients starting PCSK9 therapy now shifts toward the oral option, because in chronic disease management, convenience wins.
Novo’s Wegovy Pill Cleared Europe
What Happened: The European Commission granted marketing authorization for the Wegovy pill (once daily oral semaglutide 25 mg) for adults with obesity or overweight with a weight related comorbidity.
Why This Matters: The obesity market’s next phase is about access and convenience as much as raw efficacy. An approved oral Wegovy in Europe gives needle averse patients a branded pill option in one of the world’s largest pharmaceutical markets. It lands in the same period that Lilly’s oral Foundayo gained approval, the Medicare Bridge launched at $50 per month for both companies’ products, and Kailera’s oral obesity drug won its China Phase 3.
The oral obesity race now has multiple players in multiple markets. Foundayo in the United States. Oral Wegovy in Europe (and already approved in the U.S.). Kailera’s oral GLP 1 advancing out of China. The competition is playing out on two dimensions simultaneously: geographic expansion (which oral drug reaches which market first) and clinical differentiation (which drug offers the best combination of weight loss, tolerability, and dosing convenience). For European physicians and patients, oral Wegovy gives them what the U.S. market has had since Foundayo: a real alternative to injection for people who want the benefit of GLP 1 therapy without the needle.
The China Deadline Lands, But the Industry Already Answered
What Happened: Today Merck, AbbVie, Lilly, Pfizer, and BMS owe the House Select Committee on China detailed answers on their clinical trials at sites in Xinjiang and at hospitals affiliated with China’s military. The committee, led by Chairman Moolenaar with ranking member Krishnamoorthi, has been explicit that it has found no evidence of wrongdoing.
The Month Told the Story
We have tracked this deadline since the probe opened on June 29. Here is what happened in the three weeks between the probe and the deadline:
AstraZeneca signed five China deals since the start of 2025, including two this month alone—the CSPC kidney collaboration ($1.77 billion) and the Dizal Zegfrovy license ($600 million upfront). BioNTech committed $1 billion to DualityBio for ADCs. Kailera read out positive Phase 3 data from Hengrui licensed assets. Hansoh’s GSK partnered ADC hit its overall survival endpoint in small cell lung cancer. HUYABIO’s BMS partnered melanoma drug cleared Phase 3. And AstraZeneca was not even among the five named companies.
The political pressure did not slow anyone down. Not one visible deal was delayed, restructured, or withdrawn in response to the probe. China’s share of early drug development climbed from 8% in 2015 to over 32% by 2024, and U.S. companies spent a record $138 billion licensing Chinese assets last year. The momentum is too powerful for a congressional letter to redirect.
The Real Fight Is Not Today
The responses go to the committee, not to the public, so expect them to surface in fragments over the coming days rather than as a single reveal. The five companies will submit detailed compliance narratives emphasizing ethical review, data protection, and IP safeguards. They will not concede wrongdoing, because the committee explicitly said it found none.
The deadline is a milestone, not a resolution. The real fight is the Biotech Investment National Security Act, which would route China licensing deals through Treasury review. That legislation has not yet received a committee vote. Whether it advances depends on whether the July 17 responses satisfy the committee or fuel further investigation. Our read, unchanged since June: the deals already signed are safe. New deals continue at a rising political cost. The friction gets priced and paid rather than avoided. And the quiet irony remains as sharp as ever: Merck’s sac TMT, one of the company’s most promising cancer drugs, came out of exactly the China licensing model now under congressional scrutiny.
Merck’s sac TMT Keeps Rolling in Endometrial Cancer
What Happened: Merck’s sac TMT, partnered with China’s Kelun Biotech, hit in a Phase 3 endometrial cancer trial, following a recent positive global Phase 3 readout in the same cancer.
Why This Matters: The Trop 2 ADC continues to be one of the most productive assets in Merck’s oncology pipeline. It has now delivered positive Phase 3 data in lung cancer (65% PFS improvement over Keytruda alone) and endometrial cancer, with global filings expected in the second half of 2026. For Merck’s post Keytruda diversification strategy, sac TMT is essential. Keytruda faces patent cliff exposure in 2028, and every additional indication and filing that sac TMT accumulates builds the replacement franchise that Merck needs.
The China connection is impossible to ignore on deadline day. sac TMT was developed through a partnership with Kelun Biotech, a Chinese company. It is a Chinese originated drug producing the kind of pivotal data that justify the entire China licensing model. The same week that Congress asks why American pharma companies are in China, one of the most persuasive answers is sitting in Merck’s endometrial cancer data package.
Strategic Themes
1. Lilly at Fifteen Deals Is No Longer Just Doing Deals—It Is Building a New Kind of Pharmaceutical Company
Obesity, oncology, cell therapy, gene editing, vaccines, pain, myelofibrosis, kidney disease, narcolepsy, gene delivery, China partnerships, and now psychedelics. No company in the history of the pharmaceutical industry has assembled this breadth in this timeframe. The December 7 Investment Community Meeting will need to explain how fifteen deals across ten therapeutic areas and eight modalities integrate into a coherent strategy. The acquisitive pace raises the obvious question: can any organization absorb this much external innovation simultaneously? The answer will determine whether Lilly emerges as the most diversified pharmaceutical company ever built or whether the integration challenge overwhelms the strategic vision.
2. An Oral PCSK9 Expands the Cholesterol Market Rather Than Just Splitting It
When powerful mechanisms move from injection to oral, the number of treated patients increases because the barrier was never the science—it was the delivery. Lipfendra gives physicians a tool they have wanted for years: the LDL lowering potency of PCSK9 inhibition in a daily pill. For the millions of patients who need more cholesterol lowering than statins provide but are unwilling to start injections for a condition they cannot feel, oral PCSK9 changes the conversation from “would you consider a shot?” to “here is a pill.” That is a market expansion, not a share theft.
3. The China Deadline Is Theater, and the Legislation Is the Weapon
We called this in June and nothing in the past three weeks has changed the read. The probe generated headlines. The deals kept flowing. AstraZeneca signed five deals since 2025 and put $600 million upfront on an approved Chinese drug three days before the deadline. The five named companies will submit careful letters and move on. The real threat to the China licensing model is the Biotech Investment National Security Act, which would add Treasury review to every deal. Whether that bill advances after the committee digests the July 17 responses is the question that actually determines whether the China pipeline’s political cost goes from manageable friction to structural impediment.
4. Merck’s sac TMT on Deadline Day Is the China Debate in One Data Point
A Chinese originated drug. Developed through a Chinese partnership. Producing Phase 3 data in endometrial cancer that Merck needs for its post Keytruda future. Delivered the same day Congress demands answers about American pharma’s China engagement. The clinical value and the political risk live in the same molecule. That tension does not resolve on a deadline. It gets managed, deal by deal, indication by indication, for years.
Frequently Asked Questions
What is the Lilly/AtaiBeckley deal?
Lilly is acquiring AtaiBeckley for up to $3.8 billion, entering psychedelic based mental health treatment. It is roughly Lilly’s fifteenth deal of 2026. The acquisition legitimizes the psychedelic medicine category and follows Compass Pathways’ durable Phase 3 depression data from last week.
What is Lipfendra?
Merck’s enlicitide, the first oral PCSK9 inhibitor. Approved by the FDA for lowering LDL cholesterol. Removes the injection barrier that held back uptake of the PCSK9 class (Amgen’s Repatha, Sanofi/Regeneron’s Praluent). Expected to expand the treated population rather than just take share from existing injectables.
Did Novo’s Wegovy pill get approved in Europe?
Yes. The European Commission granted marketing authorization for once daily oral semaglutide 25 mg for adults with obesity or overweight with comorbidities. It gives European patients an oral branded obesity option alongside injectable Wegovy.
What happened with the China deadline?
Today Merck, AbbVie, Lilly, Pfizer, and BMS must submit their responses to the House Select Committee on China. The committee found no evidence of wrongdoing. Responses go to the committee and will likely surface in fragments. The real legislative fight is the Biotech Investment National Security Act, which has not yet received a committee vote.
What is the sac TMT result?
Merck’s Trop 2 ADC (partnered with China’s Kelun Biotech) hit Phase 3 in endometrial cancer. It has now delivered positive Phase 3 data in lung cancer and endometrial cancer. Global filings expected H2 2026. A Chinese originated drug producing the data Merck needs for its post Keytruda future.
How many deals has Lilly done?
Approximately fifteen in 2026, spanning at least ten therapeutic areas and eight modalities. The most aggressive dealmaking pace in pharmaceutical history by any single company.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Lilly Just Validated Psychedelics with $3.8B. We map what the deal means for Compass Pathways, the broader psychedelic category, and the treatment resistant depression market. When the most valuable pharma company in the world pays billions for psychedelics, every company in the space and every investor watching it needs to reassess.
An Oral PCSK9 Changes the Cholesterol Market. We analyze who wins and who scrambles now that Merck has cracked oral PCSK9, model the market expansion potential versus the injectable share shift, and assess what Amgen, Sanofi, and Regeneron need to do in response.
The China Fight: How It Actually Ends. We give the three scenarios for where the China licensing debate goes after the deadline, assess which is most likely, and identify the legislative tells that will signal whether the Biotech Investment National Security Act gains real teeth or fades.
Plus: Novo oral Wegovy EU positioning, Merck sac TMT endometrial franchise, Lilly fifteen deal integration challenge, Section 232 tariff countdown (14 days), and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
